potassium (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate | 14028-61-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: potassium (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate
• 英文别名: (4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid potassium salt；(R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid; potassium salt；potassium;(4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate
• CAS: 14028-61-6
• 化学式: C₆H₉O₄*K
• 分子量: 184.233
• InChiKey: ZOISWEHAOHFWAH-PGMHMLKASA-M

物化性质

• 熔点：
  68 °C(Solv: ligroine (8032-32-4))

计算性质

• 辛醇/水分配系数(LogP)：
  -4.11
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  potassium (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 生成 D-甘油酸
  参考文献：
  名称：

  苯酚的氧化和生物合成。第十二部分。与吗啡生物碱生物合成有关的立体化学研究

  摘要：

  tri化的salutaridinols-I和-II的臭氧分解反应提供了甘油酸，其绝对构型已通过同位素稀释法确定。这样，吗啡生物碱的前体salutaridinol-I的立体化学已被明确定义。

  DOI：

  10.1039/j39670000128
• 作为产物：
  描述：

  双丙酮-D-甘露糖醇 在 氢氧化钾 作用下， 反应 21.0h， 以70%的产率得到potassium (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate
  参考文献：
  名称：

  Oxidative Cleavage of Vicinal Diols at the Nickel Hydroxide Electrode

  摘要：

  邻二醇在水性碱性电解质和未分隔的电池中，使用覆盖氧化物的镍电极通过电解进行氧化裂解，产率良好。该方法应用于合成光学纯的2,2-二甲基-1,3-二噁烷-4-羧酸衍生物。

  DOI：

  10.1055/s-1988-27462

文献信息

• SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR
  申请人：Baumann Andrew Christian

  公开号：US20060281788A1

  公开（公告）日：2006-12-14

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括管理法尼基转移酶抑制剂和从公式I'的化合物中选择的FLT3激酶抑制剂。 本发明包括用于治疗处于发展细胞增殖障碍或与FLT3相关障碍风险（或易感性）的受试者的预防和治疗方法。
• METHOD OF INHIBITING C-KIT KINASE
  申请人：Illig R. Carl

  公开号：US20080051402A1

  公开（公告）日：2008-02-28

  A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明提供了一种减少或抑制细胞或主体中C-KIT激酶活性的方法，以及使用本发明的化合物预防或治疗主体中的细胞增殖障碍和/或与C-KIT相关疾病的应用：或其溶剂化物、水合物、互变异构体或药用可接受盐。本发明进一步涉及治疗癌症和其他细胞增殖障碍等条件的方法。
• Synthesis and Structure–Activity Relationship Studies of C2-Modified Analogs of the Antimycobacterial Natural Product Pyridomycin
  作者：Maryline Kienle、Patrick Eisenring、Barbara Stoessel、Oliver P. Horlacher、Samuel Hasler、Gwénaëlle van Colen、Ruben C. Hartkoorn、Anthony Vocat、Stewart T. Cole、Karl-Heinz Altmann

  DOI：10.1021/acs.jmedchem.9b01457

  日期：2020.2.13

  A series of derivatives of the antimycobacterial natural product pyridomycin have been prepared with the C2 side chain attached to the macrocyclic core structure by a C-C single bond, in place of the synthetically more demanding enol ester double bond found in the natural product. Hydrophobic C2 substituents of sufficient size generally provide for potent anti-Mtb activity of these dihydropyridomycins

  已经制备了一系列抗分枝杆菌天然产物吡咯霉素的衍生物，其中C2侧链通过CC单键连接到大环核心结构上，代替了天然产物中合成上要求更高的烯醇酯双键。足够大小的疏水性C2取代基通常为这些二氢吡啶霉素提供强大的抗Mtb活性（最小抑制浓度（MIC）约为2.5μM），因此一些类似物接近天然吡咯霉素的活性。令人惊奇地，与吡啶霉素相反，这些化合物中的一些对结核分枝杆菌（Mtb）中InhA的过表达不敏感。
• [EN] HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY<br/>[FR] DERIVES AMIDES HETEROCYCLIQUES POSSEDANT UNE ACTIVITE INHIBITRICE DE GLYCOGENE PHOSPHORYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2005018637A1

  公开（公告）日：2005-03-03

  A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example: R4 and R5 together are either -S-C(R6=C(R7)- or -C(R7)=C(R6)-S- ; R6 and R7 are independently selected from hydrogen and halo; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is halo, cyano or carboxy; R2 is for example methyl; R3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  该化合物的分子式为（1）或其药用可接受的盐或前药；（1）其中，例如：R4和R5一起是-S-C(R6=C(R7)-或-C(R7)=C(R6)-S-；R6和R7分别选择自氢和卤素；A是苯基或杂环芳基；n为0、1或2；R1为卤素、氰基或羧基；R2为例如甲基；R3为例如选择自卤(1-4C)烷基、二卤(1-4C)烷基、三氟甲基、羟基(1-4C)烷基、二羟基(2-4C)烷基、三羟基(3-4C)烷基、氰基(1-4C)烷基（在烷基上可选择性地取代羟基）、（1-4C)烷氧基(1-4C)烷基、（1-4C)烷氧基(1-4C)烷氧基(1-4C)烷基、二[(1-4C)烷氧](1-4C)烷基、(羟基)[(1-4C)烷氧](1-4C)烷基；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备化合物和含有它们的药物组合物的方法。
• Synthesis of (S)-(+)-methyl .BETA.,.GAMMA.-dihydroxy-.ALPHA.-methylenebutyrate and (S)-(-)-tulipalin B.
  作者：Akira TANAKA、Kyohei YAMASHITA

  DOI：10.1271/bbb1961.44.199

  日期：——

  The synthesis of (S)-(+)-methyl β, γ-dihydroxy-α-methylenebutyrate and (S)-(-)-tulipalin B, antibacterial substances isolated from Spiraea thunliergii Sieb. has been accomplished starting from isopropylidene-D-glyceraldehyde.

  已成功合成(S)-(+)-甲基β, γ-二羟基-α-亚甲基丁酸酯和(S)-(-)-郁金香醇B，这些是从Thunberg的海枣(SPIRAEA thunbergii Sieb.)中分离的抗菌物质，起始原料为异丙基羟基-D-甘油醛。